NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Contract Research Organizations (CRO) M&A update, 14–28 September 2026

A bi-weekly update on Contract Research Organizations covering price moves, company announcements and the M&A transaction record for September 14–28, 2026, for operators, acquirers and advisers tracking the sector.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Contract Research Organizations (CRO) Sector Outlook — September 2026

Key figures

Sector median move
+2.0%
vs +0.8% S&P 500, close-to-close
AbCellera Biologics (ABCL)
+24.6%
period high, following ABCL635 Phase 2 data
Cellectis S.A. (CLLS)
-19.1%
period low, amid strategy reset and legal cluster
Precedent transaction median
13.3x
35 recorded deals, EV/LTM EBITDA

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO)

Platform News Sets the Price While Services Names Move Quietly

This update covers what moved, what companies announced and what the transaction record showed across September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across September 14–28, 2026, CRO sector price action concentrated in platform names: AbCellera Biologics Inc. (ABCL) rose +24.6% after presenting Phase 2 data for ABCL635, while Cellectis S.A. (CLLS) fell -19.1% amid a strategy reset and a cluster of investor law firm investigations. Breadth was positive overall, with 5 of 9 covered names higher and the median move of +2.0% ahead of the S&P 500's +0.8%. No new transactions entered the precedent record, leaving the standing benchmark of 35 deals at a median 13.3x EV/EBITDA as the reference point for acquirers.

Key findings

  • Program data drove the period's biggest gain and its biggest loss
  • Breadth ran positive, outpacing the S&P 500 on a median basis
  • No new M&A prints; precedent transactions still anchor valuation
  • Services delivery stayed calm while platform news set prices

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO)

    This is the cover page for the CRO bi-weekly industry events and M&A update covering September 14–28, 2026.

    We open with the two-week window this update covers, September 14–28, 2026, across the Contract Research Organizations sector. The pages that follow walk through what moved, what companies announced, and what the transaction record showed.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO) Platform News Sets the Price While Services Names Move Quietly This update covers what moved, what companies announced and what the transaction record showed across September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Program Data and Legal Overhang Did the Moving; The Services Half Stayed Calm

    This slide summarizes the two-week period's key movements across program data and legal overhang versus stable services activity.

    We find breadth ran positive and outpaced the index: 5 of 9 covered names rose, with the median move at +2.0% against +0.8% for the S&P 500. AbCellera Biologics Inc. (ABCL) delivered the period's largest gain at +24.6%, including +9.6% on September 28, following its September 16 presentation of Phase 2 data for ABCL635. Cellectis S.A. (CLLS) posted the largest decline at -19.1%, with -14.3% of that on September 16, alongside a board-approved strategy shift and investor law firm investigations disclosed in the same window. So the period's price action sat with program data and legal overhang, not with scaled services delivery.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Program Data and Legal Overhang Did the Moving; The Services Half Stayed Calm The two-week period in one page · 9 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Breadth Leaned Positive and Ran Ahead of the Index 5 of 9 covered names rose; the median move was +2.0%, against +0.8% for the S&P 500. The largest gain and the largest fall both landed on platform names rather than on scaled services delivery. 2 Program Data Drew the Period's Largest Reward AbCellera Biologics Inc. (ABCL) rose +24.6%, with +9.6% of that on Sep 28. The in-window item that speaks to it is the September 16 presentation of Phase 2 data for ABCL635, and a September 22 Zacks piece put the three-month run at 121%. 3 A Strategy Reset and a Legal Cluster Sat Under the Worst Move Cellectis S.A. (CLLS) fell -19.1%, including -14.3% on Sep 16. A Discount-tier name in NeuraCap's standing view, it announced a board-approved shift to in vivo gene editing on September 14, and several investor law firm investigations were announced in the same window. 4 The Precedent Record, Not New Deals, Carries the Benchmark Nothing was added to the transaction record this period. The trailing set of 35 precedent transactions carries a median of 13.3x EV/EBITDA, while NeuraCap's standing lens sits at 3.1x EV/Revenue on CY2027E, with the Premium tier at 11.1x and the Discount tier at 0.8x. +24.6% Best mover — AbCellera Biologics Inc. (ABCL) worst: CLLS -19.1% · 5 up / 4 down of 9 covered +2.0% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    Two Price Bands, Two Very Different Fortnights

    This slide details the two-week price moves across covered names, split between platform and services names.

    We see two price bands this period: the sector median moved +2.0%, ahead of the S&P 500's +0.8%, against a materiality bar of ±11.8%. AbCellera Biologics Inc. (ABCL) cleared that bar decisively at +24.6%, while Cellectis S.A. (CLLS) cleared it on the downside at -19.1%. Every other covered name moved inside the bar, keeping the services half of the sector calm. So the dispersion this period concentrated in platform names rather than spreading broadly.

    Everything on this page

    PUBLIC MARKET MOVERS Two Price Bands, Two Very Different Fortnights Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +2.0% · S&P 500 +0.8% · materiality bar ±11.8% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +2.0% AbCellera Biologics Inc. (ABCL) +24.6% Shares moved following the September 16 presentation of Phase 2 data for ABCL635 at the IMS World Congress on Menopause. A September 22 Zacks piece linked the run to that data, partnerships and a stronger financial position. The platform half of this market gets paid for program data, not for billable hours. COMPANY-SPECIFIC Cellectis S.A. (CLLS) -19.1% The move followed the September 14 announcement that the board approved a strategic transformation into an in vivo gene editing company, and a run of securities fraud investigations announced from September 16. Repositioning a platform mid-course invites questions about what the earlier story promised. COMPANY-SPECIFIC Fortrea Holdings Inc. (FTRE) +15.2% No notable in-window news was identified that clearly explains the move. The +15.2% gain ran well ahead of the +2.0% median across the covered set. A Core-tier services name can travel far ahead of the covered set without a disclosure attached to it. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    What Companies Did: One Strategy Reset, One Capability Push, One Legal Cluster

    This slide covers the period's highest-impact company announcements: a strategy reset, a capability push, and a legal cluster.

    We highlight three threads from the two weeks: a strategy reset at Cellectis S.A. (CLLS), announced September 14, toward in vivo gene editing; a capability push at AbCellera Biologics Inc. (ABCL), which presented Phase 2 data for ABCL635 on September 16; and a cluster of investor law firm investigations announced around Cellectis in the same window. Each item links back to its underlying filing or article rather than to a market reaction alone. So the news flow this period was narrow in names but substantive in content.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS What Companies Did: One Strategy Reset, One Capability Push, One Legal Cluster The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 14 · NEWS · GlobeNewsWire Cellectis board approves a strategic transformation into an in vivo gene editing company This is the platform end of the market changing what it sells. A move of this kind shifts the value question from current fee income to future programme economics When a platform redefines its asset base, the valuation lens has to be restated with it. Sep 14 · NEWS · Business Wire OmniAb confirms an Investor & Analyst Day for October 6 and reiterates the details A Premium-tier name choosing a full investor session signals it wants the partnership pipeline and platform economics judged on their own terms rather than on quarterly noise. Platform names compete for attention on programme participation, not on delivery volume. Sep 23 · NEWS · Business Wire Late-breaker Phase 2a data for EVO301 in atopic dermatitis presented at the EADV 2026 Congress Partnered molecule readouts are where discovery platforms show whether their engine converts into downstream economics. Clinical readouts on partnered assets are the platform equivalent of a backlog update. Sep 22 · NEWS · GlobeNewsWire Another investor law firm announces an investigation into claims on behalf of Cellectis investors Repeat legal filings extend the overhang beyond a single news day and put earlier disclosure under review. Counterparties tend to price that uncertainty into diligence timelines. Legal process risk is priced alongside programme risk at the platform end of this market. Sep 19 · NEWS · Business Wire Shareholder law firm invites Cellectis investors to join a fraud investigation A cluster of investigations rather than one signals sustained scrutiny of the disclosure record, which is the kind of item that slows partnership and transaction conversations. Clean disclosure history travels with a platform the way a clean inspection record travels with capacity. Sep 17 · NEWS · Business Wire Charles River introduces rapid cell banking programs to accelerate release timelines Cycle time is a commercial lever for regulated capacity, not a back-office metric. A Core-tier name putting rapid and in vitro methods behind release timelines is competing on study startup speed and throughput. Faster release timelines protect utilisation and make preferred provider status harder to displace.

  5. 05
    M&A & STRATEGIC ACTIVITY

    No New Prints, so the Standing Benchmark Does the Work

    This slide shows the standing precedent transaction benchmark since no new deals were recorded in the period.

    No new transactions entered the record this period, so the standing benchmark carries the page: 35 precedent transactions at a median of 13.3x EV/LTM EBITDA. NeuraCap's standing sector lens sits at 3.1x EV/Revenue on CY2027E, with the Premium tier at 11.1x and the Discount tier at 0.8x. We read this as a quiet stretch for dealmaking rather than a shift in valuation discipline. So the existing benchmark remains the most current reference point available to buyers.

    Everything on this page

    M&A & STRATEGIC ACTIVITY No New Prints, so the Standing Benchmark Does the Work September 14–28, 2026 · precedent transactions: 35 recorded deals · median 13.3x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing set of 35 precedent transactions still carries a median of 13.3x EV/EBITDA, which remains the reference buyers are working from. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 35 Recorded precedent transactions the reference set buyers and sellers price against 13.3x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

  6. 06
    WHAT IT MEANS

    What the Period Changes for Operators, Buyers and Advisers

    This slide translates the period's evidence into observations for operators, acquirers and advisers.

    For operators, the period's gains sit on operating fundamentals such as net new business awards, book-to-bill and funded backlog rather than on headline events alone. For acquirers, the reference set is unchanged at 35 precedent transactions and a median of 13.3x EV/EBITDA, against a standing sector lens of 3.1x EV/Revenue on CY2027E. For advisers, the split between AbCellera Biologics Inc. (ABCL) at +24.6% and Cellectis S.A. (CLLS) at -19.1% illustrates how differently platform economics and service capacity are being priced right now. So the period reinforces a two-business read of the sector rather than a single narrative.

    Everything on this page

    WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.1x 11 companies in the study 3 valuation tiers Standing thesis: Contract Research Organizations Price as Two Businesses: Service Capacity and Partnership Platforms FOR OWNERS & OPERATORS Companies in the Space Traded Higher on Balance 5 of 9 covered names rose; the median move was +2.0%. The operating work behind that is unglamorous: net new business awards, book-to-bill, funded backlog and its burn, billable utilisation and study startup cycle time. FOR ACQUIRERS The Reference Set Is Unchanged, but the Platform Read Is Sharper Nothing entered the transaction record this period, so the benchmark stays where it was: 35 precedent transactions at a median of 13.3x EV/EBITDA, against a standing sector lens of 3.1x EV/Revenue on CY2027E. FOR ADVISORS Lead with the Split Between Service Capacity and Platform Economics The period supports the standing view that this sector prices as two businesses. Lead with the evidence: AbCellera Biologics Inc. (ABCL) at +24.6% following the ABCL635 Phase 2 presentation, Cellectis S.A.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This slide sets out the sources and methodology behind the update's figures and analysis.

    This update draws on SEC filings, company disclosures and market prices through September 28, 2026, with publisher-sourced news linked where used. Figures are taken directly from those records, and driver attributions reflect a calibrated reading of the recorded evidence rather than asserted causation. So every statement in this update traces back to a source a reader can open.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Contract Research Organizations (CRO) Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T212031Z_572_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · businesswire.com

Sources and methodology

This update covers Contract Research Organizations (CRO) over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Contract Research Organizations (CRO) under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AbCellera Biologics Inc. (ABCL), Aclaris Therapeutics, Inc. (ACRS), C4 Therapeutics, Inc. (CCCC), Cellectis S.A. (CLLS), Charles River Laboratories International, Inc. (CRL), Evotec SE (EVO), Fortrea Holdings Inc. (FTRE), IQVIA Holdings Inc. (IQV), OmniAb, Inc. (OABI). 2 names below the floor were excluded from the statistics: CSBR, HYFT.

Window and company universe

This update covers Contract Research Organizations (CRO) over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Contract Research Organizations (CRO) under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AbCellera Biologics Inc. (ABCL), Aclaris Therapeutics, Inc. (ACRS), C4 Therapeutics, Inc. (CCCC), Cellectis S.A. (CLLS), Charles River Laboratories International, Inc. (CRL), Evotec SE (EVO), Fortrea Holdings Inc. (FTRE), IQVIA Holdings Inc. (IQV), OmniAb, Inc. (OABI). 2 names below the floor were excluded from the statistics: CSBR, HYFT.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 35 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Contract Research Organizations (CRO)?

Company valuation reports run the same method against a single business — public or private.